严重肢体威胁性缺血血管内治疗的结果
本文评估150例伴缺血性溃疡的严重肢体威胁性缺血(CLTI)患者接受血管内治疗优先策略的结局;平均年龄72岁,吸烟史49%、糖尿病67%,仅35.6%肢体解剖适合长期通畅;24个月再干预36%,12与24个月无截肢生存率分别为0.56与0.38。作者结论认为尽管血管内治疗技术成功,患者肢体丧失与死亡风险仍高,截肢预防须警惕感染风险,数据与BEST-CLI试验结果相符。
要点
- 150例伴缺血性溃疡的CLTI患者接受血管内治疗优先策略,24个月内再干预率36%。
- 12与24个月无截肢生存率分别为0.56与0.38,截肢率分别为0.69与0.59。
- 接受再干预者截肢更常见(P = 0.033),任何感染可预测无截肢生存(P = 0.0001)。
核心结论
- 尽管血管内治疗技术成功,伴缺血性溃疡的CLTI患者肢体丧失与死亡风险仍高,截肢预防须警惕感染风险。
- 作者认为本数据与BEST-CLI试验结果相符,增强了对以患者为中心照护的适用性。
研究设计与样本
- 本研究为单臂评估,纳入150例伴缺血性溃疡的CLTI患者,接受血管内治疗优先策略,平均年龄72岁,以男性、白人、可步行者为主。
- 合并症包括吸烟史49%与糖尿病67%;采用血管外科学会标准进行解剖评分,47%病例使用支架。
主要发现
- 血管外科学会标准解剖评分显示,35.6%肢体解剖适合长期通畅(GLASS 0、1期),64.4%肢体解剖不适合长期通畅(GLASS 2、3期)。
- 24个月随访期间再干预发生率为36%。
关键数值与推荐
- 接受再干预者截肢更常见(P = 0.033)。
- 踝肱指数≤0.40或≥1.30(P = 0.0019)及感染存在(P = 0.0047)可预测死亡。
- 任何感染的存在可预测无截肢生存(P = 0.0001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Critical limb threatening ischemia (CLTI), particularly in patients with ischemic ulceration has been associated with significant morbidity and mortality. Typically, endovascular therapy has been first-line therapy for our patients, but this strategy has come into question based upon the Best Endovascular versus Best Surgical Therapy in Patients with Critical Limb Threatening Ischemia (BEST-CLI) trial data. METHODS AND RESULTS: For comparative purposes, we evaluated outcomes from 150 CLTI patients with ischemic ulceration treated with endovascular-first therapy. The mean age was 72 years in this predominate male, Caucasian, ambulatory group. The major co-morbidities were smoking history in 49% and diabetes mellitus in 67%.` Anatomic scoring, using Society for Vascular Surgery criteria, revealed only 35.6% had favorable anatomy (Global Limb Anatomical Staging System stage of 0,1) for long-term patency compared to 64.4% of limbs with unfavorable anatomy for long-term patency (Global Limb Anatomical Staging System stage 2,3). Stents were used in 47% of cases. Reintervention occurred in 36% over 24 months follow-up. At 12 and 24 months, the Kaplan-Meier projections for survival was 0.80 (0.73, 0.87) and 0.69 (0.59, 0.79); amputation was 0.69 (0.61, 0.77) and 0.59 (0.46, 0.71); amputation-free survival (AFS) was 0.56 (0.48, 0.65) and 0.38 (0.27, 0.50), respectively. Amputation was more common in those with reinterventions (P = 0.033). Mortality was predicted with ankle brachial index ≤0.40 or ≥1.30 (P = 0.0019) and the presence of infection (P = 0.0047). AFS was predicted by the presence of any infection (P = 0.0001). CONCLUSIONS: Despite technically successful endovascular treatment, patients who present with CLTI maintain a high-risk for limb loss and mortality. Amputation prevention must vigilantly address infection risk. These data correlate with outcomes from BEST-CLI trial enhancing applicability to patient-centered care.
引用
- Beucler A, Wheibe E, Gandhi SS, et al. Outcomes of Endovascular Treatment for Critical Limb Threatening Ischemia. Ann Vasc Surg. 2023. PMID: 37922961. doi:10.1016/j.avsg.2023.09.077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。